Bright Minds Biosciences Inc.
DRUG · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $580,749 | $6,820 | $8,077 | $21,007 |
| - Cash | $82,909 | $5,720 | $6,748 | $11,628 |
| + Debt | $126 | $119 | $74 | $140 |
| Enterprise Value | $497,966 | $1,219 | $1,402 | $9,519 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$55 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$8,700 | $0 | -$7,280 | -$14,726 |
| % Margin | – | – | – | – |
| Net Income | -$12,229 | -$2,802 | -$7,372 | -$14,965 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.28 | -0.65 | -1.98 | -6.15 |
| % Growth | -96.9% | 67.2% | 67.8% | – |
| Operating Cash Flow | -$6,241 | -$1,850 | -$7,024 | -$13,587 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$6,241 | -$1,850 | -$7,024 | -$13,587 |